In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

NEW YORK, Jan. 22 (UPI) --As demand for weight-loss injections sold under ... The medications are known as glucagon-like peptide-1 receptor agonists (GLP-1RA) and include Mounjaro and Zepbound ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase ... Journal’s annual “Best on the Street” analysts ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...